1
|
Jacobsen E: Anaplastic large-cell
lymphoma, T-/null-cell type. Oncologist. 11:831–840. 2006.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Keech JA Jr and Creech BJ: Anaplastic
T-cell lymphoma in proximity to a saline-filled breast implant.
Plast Reconstr Surg. 100:554–555. 1997. View Article : Google Scholar : PubMed/NCBI
|
3
|
FDA: Anaplastic large cell lymphoma (ALCL)
in women with breast implants: Preliminary FDA findings and
analyses. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htmJune
7–2016.
|
4
|
Clemens MW, Medeiros LJ, Butler CE, Hunt
KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA,
Kanagal-Shamanna R, et al: Complete surgical excision is essential
for the management of patients with breast implant-associated
anaplastic large-cell lymphoma. J Clin Oncol. 34:160–168. 2016.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Miranda RN, Aladily TN, Prince HM,
Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat
G, Brooks GS, et al: Breast implant-associated anaplastic
large-cell lymphoma: Long-term follow-up of 60 patients. J Clin
Oncol. 32:114–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Adrada BE, Miranda RN, Clemens M, et al:
Breast implant-associated anaplastic large cell lymphoma: Analysis
of imaging studies in 44 patients reveals need for systematic
assessment of mass versus no mass to improve diagnostic accuracy.
Plast Reconstr Surg. 4:134: S95–S96. 2014.
|
7
|
Pro B, Advani R, Brice P, Bartlett NL,
Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M,
Connors JM, et al: Brentuximab vedotin (SGN-35) in patients with
relapsed or refractory systemic anaplastic large-cell lymphoma:
Results of a phase II study. J Clin Oncol. 30:2190–2196. 2012.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Zimmerman A, Locke FL, Emole J, Rosa M,
Horna P, Hoover S and Dayicioglu D: Recurrent systemic anaplastic
lymphoma kinase-negative anaplastic large cell lymphoma presenting
as a breast implant-associated lesion. Cancer Control. 22:369–373.
2015.PubMed/NCBI
|
9
|
O'Connor OA; Columbia University, :
BBrentuximab Vedotin and Bendamustine for the Treatment of Hodgkin
Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) (SGN+Benda).
https://clinicaltrials.gov/ct2/show/NCT01657331June
7–2016.
|
10
|
Seattle Genetics, Inc., . ECHELON-2: A
Comparison of Brentuximab Vedotin and CHP With Standard-of-care
CHOP in the Treatment of Patients With CD30-positive Mature T-cell
Lymphomas (ECHELON-2). https://clinicaltrials.gov/ct2/show/NCT01777152June
7–2016.
|
11
|
Seattle Genetics, Inc, . Brentuximab
Vedotin+Rituximab as Frontline Therapy for Pts w/CD30+ and/or
EBV+Lymphomas. https://clinicaltrials.gov/ct2/show/NCT01805037June
7–2016.
|
12
|
National Cancer Institute, . Brentuximab
Vedotin or Crizotinib and Combination Chemotherapy in Treating
Patients With Newly Diagnosed Stage II–IV Anaplastic Large Cell
Lymphoma. https://clinicaltrials.gov/ct2/show/NCT01979536June
7–2016.
|
13
|
Fanale MA, Horwitz SM, Forero-Torres A,
Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T,
Huebner D, et al: Brentuximab vedotin in the front-line treatment
of patients with CD30+ peripheral T-cell lymphomas: Results of a
phase I study. J Clin Oncol. 32:3137–3143. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Ogura M, Tobinai K, Hatake K, Ishizawa K,
Uike N, Uchida T, Suzuki T, Aoki T, Watanabe T, Maruyama D, et al:
Phase I/II study of brentuximab vedotin in Japanese patients with
relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic
anaplastic large-cell lymphoma. Cancer Sci. 105:840–846. 2014.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Bartlett NL, Chen R, Fanale MA, Brice P,
Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt
JD, et al: Retreatment with brentuximab vedotin in patients with
CD30-positive hematologic malignancies. J Hematol Oncol. 7:242014.
View Article : Google Scholar : PubMed/NCBI
|